Lead optimization studies of cinnamic amide EP2 antagonists

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4173-4184

  Ganesh, Thota ^a   Jiang, Jianxiong ^a   Yang, Myung Soon ^a   Dingledine, Ray ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (TRIFLUOROMETHYL) 1H INDOL 1 YL]ETHANAMINE; 3 [3,4 BIS (2 HYDROXYETHOXY)PHENYL] N [2 (2 METHYL 1H INDOL 1 YL)ETHYL]ACRYLAMIDE; 3 [3,4 BIS (2 HYDROXYETHOXY)PHENYL] N [2 (2 METHYL 1H INDOL 3 YL)ETHYL]ACRYLAMIDE; 3 [3,4 BIS (2 HYDROXYETHOXY)PHENYL]ACRYLIC ACID; AMIDE; ETHYL 3 [3,4 BIS [2 [(TERT BUTYLDIMETHYLSILYL)OXY]ETHOXY]PHENYL]ACRYLATE; INDAZOLE DERIVATIVE; N [2 [2 (TRIFLUOROMETHYL) 1H INDOL 1 YL]ETHYL] 3 (3,4,5 TRIMETHOXYPHENYL)ACRYLAMIDE; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIOLOGICAL ACTIVITY; CYTOTOXICITY; DRUG HALF LIFE; DRUG SYNTHESIS; LIVER MICROSOME; NEUROPROTECTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; CELL LINE, TUMOR; CINNAMATES; HUMANS; MICROSOMES, LIVER; RATS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901264931     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5000672     Document Type: Article

References (61)

1. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease Neurobiol. Aging 2000, 21, 383-421
2. Heneka, M. T.; O'Banion, M. K. Inflammatory processes in Alzheimer's disease J. Neuroimmunol. 2007, 184, 69-91
3. McGeer, P. L.; McGeer, E. G. Inflammatory processes in amyotrophic lateral sclerosis Muscle Nerve 2002, 26, 459-470
4. Nagamoto-Combs, K.; McNeal, D. W.; Morecraft, R. J.; Combs, C. K. Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury J. Neurotrauma 2007, 24, 1719-1742
5. Przedborski, S. Inflammation and Parkinson's disease pathogenesis Mov. Disord. 2010, 25 (Suppl. 1) S55-S57
6. Ramlackhansingh, A. F.; Brooks, D. J.; Greenwood, R. J.; Bose, S. K.; Turkheimer, F. E.; Kinnunen, K. M.; Gentleman, S.; Heckemann, R. A.; Gunanayagam, K.; Gelosa, G.; Sharp, D. J. Inflammation after trauma: microglial activation and traumatic brain injury Ann. Neurol. 2011, 70, 374-383
7. Vezzani, A.; Aronica, E.; Mazarati, A.; Pittman, Q. J. Epilepsy and brain inflammation Exp. Neurol. 2013, 244, 11-21
8. Vezzani, A.; French, J.; Bartfai, T.; Baram, T. Z. The role of inflammation in epilepsy Nat. Rev. Neurol. 2011, 7, 31-40
9. Ho, L.; Pieroni, C.; Winger, D.; Purohit, D. P.; Aisen, P. S.; Pasinetti, G. M. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease J. Neurosci. Res. 1999, 57, 295-303
10. Lucas, S. M.; Rothwell, N. J.; Gibson, R. M. The role of inflammation in CNS injury and disease Br. J. Pharmacol. 2006, 147 (Suppl. 1) S232-S240
11. Minghetti, L. Role of inflammation in neurodegenerative diseases Curr. Opin. Neurol. 2005, 18, 315-321
12. Pasinetti, G. M.; Aisen, P. S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain Neuroscience 1998, 87, 319-324
13. Cannon, G. W.; Caldwell, J. R.; Holt, P.; McLean, B.; Seidenberg, B.; Bolognese, J.; Ehrich, E.; Mukhopadhyay, S.; Daniels, B. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group Arthritis Rheum. 2000, 43, 978-987
14. Clemett, D.; Goa, K. L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain Drugs 2000, 59, 957-980
15. Abraham, N. S.; El-Serag, H. B.; Hartman, C.; Richardson, P.; Deswal, A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident Aliment. Pharmacol. Ther. 2007, 25, 913-924
16. Egan, K. M.; Lawson, J. A.; Fries, S.; Koller, B.; Rader, D. J.; Smyth, E. M.; FitzGerald, G. A. COX-2-derived prostacyclin confers atheroprotection on female mice Science 2004, 306, 1954-1957
17. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 2006, 116, 4-15
18. Grosser, T.; Yu, Y.; Fitzgerald, G. A. Emotion recollected in tranquility: lessons learned from the COX-2 saga Annu. Rev. Med. 2010, 61, 17-33
19. Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thal, L. J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA, J. Am. Med. Assoc. 2003, 289, 2819-2826
20. Akula, K. K.; Dhir, A.; Kulkarni, S. K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism Epilepsy Res. 2008, 78, 60-70
21. Breitner, J. C.; Baker, L. D.; Montine, T. J.; Meinert, C. L.; Lyketsos, C. G.; Ashe, K. H.; Brandt, J.; Craft, S.; Evans, D. E.; Green, R. C.; Ismail, M. S.; Martin, B. K.; Mullan, M. J.; Sabbagh, M.; Tariot, P. N. Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimer's Dementia 2011, 7, 402-411
22. Dhir, A.; Naidu, P. S.; Kulkarni, S. K. Effect of naproxen, a non-selective cyclo-oxygenase inhibitor, on pentylenetetrazol-induced kindling in mice Clin. Exp. Pharmacol. Physiol. 2005, 32, 574-584
23. Holtman, L.; van Vliet, E. A.; Edelbroek, P. M.; Aronica, E.; Gorter, J. A. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy Epilepsy Res. 2010, 91, 49-56
24. Holtman, L.; van Vliet, E. A.; van Schaik, R.; Queiroz, C. M.; Aronica, E.; Gorter, J. A. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy Epilepsy Res. 2009, 84, 56-66
25. Jung, K. H.; Chu, K.; Lee, S. T.; Kim, J.; Sinn, D. I.; Kim, J. M.; Park, D. K.; Lee, J. J.; Kim, S. U.; Kim, M.; Lee, S. K.; Roh, J. K. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus Neurobiol. Dis. 2006, 23, 237-246
26. Polascheck, N.; Bankstahl, M.; Loscher, W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy Exp. Neurol. 2010, 224, 219-233
27. Breyer, R. M.; Bagdassarian, C. K.; Myers, S. A.; Breyer, M. D. Prostanoid receptors: subtypes and signaling Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661-690
28. Hirata, T.; Narumiya, S. Prostanoid receptors Chem. Rev. 2011, 111, 6209-6230
29. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: structures, properties, and functions Physiol. Rev. 1999, 79, 1193-1226
30. Ganesh, T. Prostanoid receptor EP2 as a therapeutic target. J. Med. Chem. [Online early access]. DOI: 10.1021/jm401431x. Published Online: Nov 26, 2013.
31. Jiang, J.; Dingledine, R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Trends. Pharmacol. Sci. 2013, 34, 413-423
32. Fujino, H.; Salvi, S.; Regan, J. W. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 Mol. Pharmacol. 2005, 68, 251-259
33. Regan, J. W. EP2 and EP4 prostanoid receptor signaling Life Sci. 2003, 74, 143-153
34. Bos, J. L. Epac: a new cAMP target and new avenues in cAMP research Nat. Rev. Mol. Cell Biol. 2003, 4, 733-738
35. Quan, Y.; Jiang, J.; Dingledine, R. EP2 receptor signaling pathways regulate classical activation of microglia J. Biol. Chem. 2013, 288, 9293-9302
36. de Rooij, J.; Zwartkruis, F. J.; Verheijen, M. H.; Cool, R. H.; Nijman, S. M.; Wittinghofer, A.; Bos, J. L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 1998, 396, 474-477
37. Liang, X.; Wang, Q.; Hand, T.; Wu, L.; Breyer, R. M.; Montine, T. J.; Andreasson, K. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease J. Neurosci. 2005, 25, 10180-10187
38. Jin, J.; Shie, F. S.; Liu, J.; Wang, Y.; Davis, J.; Schantz, A. M.; Montine, K. S.; Montine, T. J.; Zhang, J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein J. Neuroinflammation 2007, 4, 2
39. Liang, X.; Wang, Q.; Shi, J.; Lokteva, L.; Breyer, R. M.; Montine, T. J.; Andreasson, K. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis Ann. Neurol. 2008, 64, 304-314
40. Montine, T. J.; Milatovic, D.; Gupta, R. C.; Valyi-Nagy, T.; Morrow, J. D.; Breyer, R. M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent J. Neurochem. 2002, 83, 463-470
41. Shie, F. S.; Breyer, R. M.; Montine, T. J. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity Am. J. Pathol. 2005, 166, 1163-1172
42. af Forselles, K. J.; Root, J.; Clarke, T.; Davey, D.; Aughton, K.; Dack, K.; Pullen, N. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist Br. J. Pharmacol. 2011, 164, 1847-1856
43. Jiang, J.; Ganesh, T.; Du, Y.; Quan, Y.; Serrano, G.; Qui, M.; Speigel, I.; Rojas, A.; Lelutiu, N.; Dingledine, R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2 Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 3149-3154
44. Jiang, J.; Quan, Y.; Ganesh, T.; Pouliot, W. A.; Dudek, F. E.; Dingledine, R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3591-3596
45. Sugimoto, Y.; Narumiya, S. Prostaglandin E receptors J. Biol. Chem. 2007, 282, 11613-11617
46. Jiang, J.; Dingledine, R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation J. Pharmacol. Exp. Ther. 2013, 344, 360-367
47. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
48. Jiang, J.; Ganesh, T.; Du, Y.; Thepchatri, P.; Rojas, A.; Lewis, I.; Kurtkaya, S.; Li, L.; Qui, M.; Serrano, G.; Shaw, R.; Sun, A.; Dingledine, R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2307-2312
49. Baxter, E. W.; Reitz, A. B. Reductive aminations of carbonyl compounds with borohydride and borane reducing agents Org. React. 2002, 59, 1-70
50. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural-products Synthesis 1981, 1-28
51. Bevan, C. D.; Lloyd, R. S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates Anal. Chem. 2000, 72, 1781-1787
52. Alavijeh, M. S.; Chishty, M.; Qaiser, M. Z.; Palmer, A. M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery NeuroRx 2005, 2, 554-571
53. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2, 3-14
54. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 2010, 37, 48-57
55. Loscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2005, 2, 86-98
56. Banu, S. K.; Lee, J.; Speights, V. O., Jr.; Starzinski-Powitz, A.; Arosh, J. A. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms Mol. Endocrinol. 2009, 23, 1291-1305
57. Donnini, S.; Finetti, F.; Solito, R.; Terzuoli, E.; Sacchetti, A.; Morbidelli, L.; Patrignani, P.; Ziche, M. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways FASEB J. 2007, 21, 2418-2430
58. Honda, T.; Segi-Nishida, E.; Miyachi, Y.; Narumiya, S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis J. Exp. Med. 2006, 203, 325-335
59. Sheibanie, A. F.; Khayrullina, T.; Safadi, F. F.; Ganea, D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis Arthritis Rheum. 2007, 56, 2608-2619
60. Sung, Y. M.; He, G.; Hwang, D. H.; Fischer, S. M. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development Oncogene 2006, 25, 5507-5516
61. Roy, S.; Eastman, A.; Gribble, G. W. Synthesis of N -alkyl substituted bioactive indolocarbazoles related to Go6976 Tetrahedron 2006, 62, 7838-7845